Cyanokit

Cyanokit is a brand name of hydroxocobalamin, approved by the FDA in the following formulation(s):

CYANOKIT (hydroxocobalamin - injectable; injection)

• 
  Manufacturer: MERCK SANTE SAS
  
  Approval date: April 8, 2011
  
  Strength(s): 5GM/VIAL (5GM/KIT) ^[RLD]

Has a generic version of Cyanokit been approved?

No. There is currently no therapeutically equivalent version of Cyanokit available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cyanokit. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Dosage form of hydroxocobalamin and its use in cyanide poisoning
  Patent 5,834,448
  Issued: November 10, 1998
  Inventor(s): Pouchol; Gerard & Bonhomme; Yves & Poulain; Marie-Laure & Duran; Michel
  Assignee(s): Merck Patent Gesellschaft mit beschrankter Haftung
  The invention relates to a new dosage form of hydroxocobalamin which serves in the treatment of cyanide poisoning and contains hydroxocobalamin in freeze-dried form. The hydroxocobalamin is freeze-dried in an acidic medium so as to be practically instantly redissolved in a neutral saline solution. The present invention also relates to a process for producing hydroxocobalamin-based pharmaceutical compositions as well as to first aid kits containing these compositions and methods of using such kits for the treatment of cyanide poisoning.
  
  Patent expiration dates:
  
  
  • November 14, 2016
    
    ✓ 
    Drug product
  
  
  
  • November 14, 2016
    
    ✓ 
    Patent use: TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • December 15, 2013 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Cyanokit Consumer Information (Drugs.com)
• Cyanokit Kit Consumer Information (Wolters Kluwer)
• Cyanokit injection Consumer Information (Cerner Multum)
• Hydroxocobalamin Consumer Information (Wolters Kluwer)
• Hydroxocobalamin Kit Consumer Information (Wolters Kluwer)
• Hydroxocobalamin injection Consumer Information (Cerner Multum)